HIT Consultant April 15, 2021
Zach Henderson, Chief Commercial Officer, Glooko

As with so many aspects of our daily lives, the impact of the COVID-19 pandemic on clinical trials was both widespread and monumental. Thousands of trials—an estimated 80% of non-COVID-19 trials—came to a halt or were interrupted by the pandemic, which challenged the ability to conduct trials safely and effectively and was complicated by the reality that trials often deal with the populations most at risk from COVID-19 exposure1.

In response, clinical researchers turned to a range of solutions to address the effects of the pandemic on trials. And while, in most cases, it’s premature to definitively determine which solutions will outlast the pandemic, probably the most widely used and enduring will be the decentralized model for conducting clinical trials,...

Topics: Biotechnology, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health
DoD, Duke, John Hopkins, HJF, physIQ Launch 18-Month COVID-19 Clinical Trial Study
Biden's First 100 Days in Healthcare: Handling the COVID-19 Pandemic, Prospects for Drug Pricing Reform, and the Notable Lack of an FDA Commissioner
Covid-19 serves as catalyst for effort to diversify clinical trial enrollment
Drug spending is climbing amid the pandemic, but not at hospitals
Adagio adds $336M for pivotal tests of drug with potential to beat Covid variants

Today's Sponsors

Curation Health

Today's Sponsors


Today's Sponsor